Compare Inovio Pharmaceuticals Inc (INO) vs TeraWulf Inc (WULF) Price & Performance

INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.

Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.

WULF trades at $18.86, up 3.85% today, but remains in a bearish technical trend. The company reported a net loss of -$661.42M in 2025 with a -611.46% net margin, though it secured a significant 20-year, $19B AI infrastructure deal with Anthropic. Analyst consensus is unanimously bullish with a $37.22 price target, citing long-term AI data center growth potential despite near-term profitability challenges.

The outlook hinges on successful execution of the Anthropic partnership to drive future revenue, but high valuation multiples and persistent losses pose substantial risks. Investors face volatility from operational cash burn and sector sentiment swings, requiring careful risk assessment against transformative AI infrastructure opportunities.